ALK and non-small cell lung carcinoma: Lorlatinib has the potential to treat ALK/ROS-positive NSCLC-inhibiting drug-resistant mutation, which has a good therapeutic effect on patients who have received more than two TKI treatments and failed to be treated, and its safety is in a controllable range (141).